In addition, Jiangsu Yanshen has received a new medicine certificate from the PRC State Food and Drug Administration (SFDA) for its freeze-dried human use rabies vaccine (vero cell).
The clinical trail of purified hepatitis A inactivated vaccine (vero cell) has already been completed.
However, SFDA’s approval for the purified hepatitis A inactivated vaccine (vero cell) and GMP certification for the associated new manufacturing facility are pending.
Jinsheng Ren, Chairman and CEO of Simcere Pharmaceutical Group, said: we are delighted to enter this new market through our investment in Jiangsu Yanshen. This is another significant development for Simcere in the biopharmaceutical area, following our recent investment in Shanghai Celgen Bio-Pharmaceutical Co., Ltd.